Annals of Hematology

, Volume 86, Issue 8, pp 609–611 | Cite as

Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia

  • Samart Pakakasama
  • Kittima Kanchanakamhaeng
  • Saowanee Kajanachumpol
  • Umaporn Udomsubpayakul
  • Nongnuch Sirachainan
  • Amnuay Thithapandha
  • Suradej Hongeng
Letter to the Editor

Notes

Acknowledgments

This work was supported by Ramathibodi Research Fund.

References

  1. 1.
    Ulrich CM, Robien K, McLeod HL (2003) Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer 3:912–920PubMedCrossRefGoogle Scholar
  2. 2.
    Lecomte T, Ferraz JM, Zinzindohoue F et al (2004) Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 10:5880–5888PubMedCrossRefGoogle Scholar
  3. 3.
    Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 100:3832–3834PubMedCrossRefGoogle Scholar
  4. 4.
    National Cancer Institute (1998) Common toxicity criteria, version 2.0. National Cancer Institute, Bethesda, MDGoogle Scholar
  5. 5.
    Yi P, Pogribny IP, James SJ (2002) Multiplex PCR for simultaneous detection of 677 C→T and 1298 A→C polymorphisms in methylenetetrahydrofolate reductase gene for population studies of cancer risk. Cancer Lett 181:209–213PubMedCrossRefGoogle Scholar
  6. 6.
    Hongeng S, Sasanakul W, Chuansumrit A, Pakakasama S, Chattananon A, Hathirat P (2000) Frequency of thiopurine S-methyltransferase genetic variation in Thai children with acute leukemia. Med Pediatr Oncol 35:410–414CrossRefGoogle Scholar
  7. 7.
    van Ede AE, Laan RF, Blom HJ et al (2001) The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. Arthritis Rheum 44:525–530Google Scholar
  8. 8.
    Shimasaki N, Mori T, Samejima H et al (2006) Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 28:64–68PubMedCrossRefGoogle Scholar
  9. 9.
    Aplenc R, Thompson J, Han P et al (2005) Methyltetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 65:2482–2487PubMedCrossRefGoogle Scholar
  10. 10.
    Berkun Y, Levartovsky D, Rubinow A, Orbach H, Aamar S, Grenader T (2004) Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann Rheum Dis 63:1227–1231PubMedCrossRefGoogle Scholar
  11. 11.
    Herrlinger KR, Cummings JRF, Barnardo MC, Schwab M, Ahmad T, Jewell DP (2005) The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenetics Genomics 15:705–711CrossRefGoogle Scholar
  12. 12.
    Cheok MH, Lugthart S, Evans WE (2006) Pharmacogenomics of acute leukemia. Ann Rev Pharmacol Toxicol 46:317–353CrossRefGoogle Scholar
  13. 13.
    Stanulla M, Schaeffeler E, Flohr T et al (2005) Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. JAMA 23:1485–1489CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Samart Pakakasama
    • 1
  • Kittima Kanchanakamhaeng
    • 1
  • Saowanee Kajanachumpol
    • 1
  • Umaporn Udomsubpayakul
    • 1
  • Nongnuch Sirachainan
    • 1
  • Amnuay Thithapandha
    • 1
  • Suradej Hongeng
    • 1
  1. 1.Department of Pediatrics and Research Center, Faculty of MedicineRamathibodi HospitalBangkokThailand

Personalised recommendations